hUCMSCs Promote Neuroprotection in Ischemic Stroke Mice by Modulating Notch Signaling
Background
Ischemic stroke (IS) remains a leading cause of long-term disability, with current treatments often limited by a narrow therapeutic window and incomplete recovery. Human umbilical cord mesenchymal stem cells (hUCMSCs) represent a promising cell-based therapy due to their regenerative and neuroprotective properties, but the underlying mechanisms are not fully elucidated. The Notch signaling pathway is a critical regulator of neural stem cell (NSC) proliferation and differentiation, yet its specific role in hUCMSC-mediated neuroprotection in IS has been unclear, representing a key gap this study addresses.
Study Design
Researchers evaluated the therapeutic effects of hUCMSCs in a mouse model of middle cerebral artery occlusion (MCAO). Fifth-generation hUCMSCs were characterized by flow cytometry for typical mesenchymal markers. In vitro, hUCMSCs were induced to differentiate with or without DAPT (a Notch inhibitor) or Jagged1 (a Notch agonist), assessing neural differentiation via Nestin and MAP2 expression. In vivo, MCAO mice received hUCMSC transplantation. Neural repair was evaluated using BrdU/Nestin immunofluorescence, qRT-PCR, Western blot, mNSS scoring, TTC, Nissl, and TUNEL assays.
Results
Characterized hUCMSCs displayed typical mesenchymal markers (CD90, CD44, CD105, and CD73) and low expression of hematopoietic markers. In vitro, DAPT significantly enhanced hUCMSC differentiation into neuron-like cells, while JAG1 reversed this effect, confirming the mechanistic role of Notch signaling. In MCAO mice, hUCMSC transplantation robustly promoted NSC proliferation and differentiation in the subventricular zone (SVZ). This led to a significant reduction in infarct volume and brain water content, an increase in Nissl-positive neurons, and a decrease in apoptotic cells. Neurological function, as measured by mNSS scores, also showed marked improvement.
Inhibition of
Notchsignaling further augmented these therapeutic effects in vivo, indicating a critical modulatory role.
Key Findings
- hUCMSCs displayed typical mesenchymal markers (CD90, CD44, CD105, CD73) and low hematopoietic markers.
- In vitro, DAPT (Notch inhibitor) enhanced hUCMSC differentiation into neuron-like cells.
- hUCMSC transplantation promoted NSC proliferation and differentiation in MCAO mice.
- hUCMSCs reduced infarct volume, brain water content, and neuronal apoptosis in MCAO mice.
- Inhibition of Notch signaling further augmented hUCMSC-mediated neuroprotection in vivo.
Why It Matters
This study significantly advances our understanding of hUCMSCs as a therapeutic strategy for ischemic stroke, highlighting their ability to promote neural differentiation and neuroprotection. The discovery that Notch signaling modulates these effects provides a crucial mechanistic insight. This opens new avenues for optimizing stem cell therapies by potentially combining hUCMSC transplantation with targeted Notch pathway modulators to enhance efficacy. Such an approach could lead to more potent and targeted interventions, moving closer to a usable protocol for improving recovery and reducing disability in stroke patients, potentially influencing future clinical trial designs for cell-based therapies.
hucmscs
ischemic stroke
notch signaling
neuroprotection
neural differentiation
stem cells